Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation

Robert J. Soiffer, René Gonin, Christine Murray, Michael Robertson, Keith Cochran, Steven Chartier, Christine Cameron, John Daley, Herbert Levine, Lee M. Nadler, Jerome Ritz

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT). Because GVHD is frequently refractory to treatment, the early identification of high-risk patients could have significant clinical value. To identify such patients, we examined early immunologic recovery in 136 patients with hematologic malignancies who received anti-T12 (CD6)-purged allogeneic bone marrow over a 9-year period. The majority of patients received marrow from HLA-matched sibling donors after ablation with cyclophosphamide and total body irradiation. No patients received any immune suppressive medications for GVHD prophylaxis. The fraction and absolute numbers of peripheral blood lymphocytes (PBL) expressing the CD3, CD4, CD8, and CD56 surface antigens were determined weekly by immunofluorescence analysis in patients beginning 8 to 14 days (week 2) after marrow infusion. Results in patients who did or did not subsequently develop GVHD post-BMT were compared. Within 2 weeks of marrow infusion, patients who developed grades 2-4 GVHD had significantly higher percentages and absolute numbers of CD8+ T cells and a lower fraction of CD56+ natural killer (NK) cells than individuals who remained free of GVHD. Thirty-five percent of patients whose PBL were greater than 25% CD8+ in the second posttransplant week developed GVHD, compared with only 3% of patients who had ≤25% CD8+ cells (odds ratio 37.8; 95% confidence interval [Cl] 4.1 to 397). A subgroup of patients at very high risk for GVHD could be identified based on the combined frequency of CD8+ T cells and NK cells in blood. Seventy-five percent of patients with greater than 25% CD8+ cells and ≤45% CD56+ cells during week 2 post-BMT developed GVHD, compared with only 11% of the remaining patients (odds ratio 24.9; 95% Cl, 5.3 to 117.0). None of the 23 patients with both less than 25% CD8+ cells and greater than 45% CD56+ cells in the second posttransplant week developed grades 2-4 GVHD. Our findings indicate that CD8+ T cells play an important role in the pathogenesis of GVHD in humans. Analysis of immune reconstitution early after BMT is useful in predicting the onset of GVHD and can help direct the implementation of treatment strategies before the appearance of clinical manifestations. Such interventions may decrease the morbidity and mortality associated with allogeneic BMT and ultimately improve overall survival.

Original languageEnglish (US)
Pages (from-to)2216-2223
Number of pages8
JournalBlood
Volume82
Issue number7
StatePublished - Oct 1 1993
Externally publishedYes

Fingerprint

Transplantation (surgical)
Homologous Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Grafts
Bone
T-cells
Bone Marrow
Blood
Lymphocytes
T-Lymphocytes
Natural Killer Cells
CD56 Antigens
Odds Ratio
Morbidity
Surface Antigens
Ablation
Mortality
Whole-Body Irradiation
Refractory materials

ASJC Scopus subject areas

  • Hematology

Cite this

Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. / Soiffer, Robert J.; Gonin, René; Murray, Christine; Robertson, Michael; Cochran, Keith; Chartier, Steven; Cameron, Christine; Daley, John; Levine, Herbert; Nadler, Lee M.; Ritz, Jerome.

In: Blood, Vol. 82, No. 7, 01.10.1993, p. 2216-2223.

Research output: Contribution to journalArticle

Soiffer, RJ, Gonin, R, Murray, C, Robertson, M, Cochran, K, Chartier, S, Cameron, C, Daley, J, Levine, H, Nadler, LM & Ritz, J 1993, 'Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation', Blood, vol. 82, no. 7, pp. 2216-2223.
Soiffer, Robert J. ; Gonin, René ; Murray, Christine ; Robertson, Michael ; Cochran, Keith ; Chartier, Steven ; Cameron, Christine ; Daley, John ; Levine, Herbert ; Nadler, Lee M. ; Ritz, Jerome. / Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. In: Blood. 1993 ; Vol. 82, No. 7. pp. 2216-2223.
@article{e8cd19b4889d42aba7edc046dd113d87,
title = "Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation",
abstract = "Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT). Because GVHD is frequently refractory to treatment, the early identification of high-risk patients could have significant clinical value. To identify such patients, we examined early immunologic recovery in 136 patients with hematologic malignancies who received anti-T12 (CD6)-purged allogeneic bone marrow over a 9-year period. The majority of patients received marrow from HLA-matched sibling donors after ablation with cyclophosphamide and total body irradiation. No patients received any immune suppressive medications for GVHD prophylaxis. The fraction and absolute numbers of peripheral blood lymphocytes (PBL) expressing the CD3, CD4, CD8, and CD56 surface antigens were determined weekly by immunofluorescence analysis in patients beginning 8 to 14 days (week 2) after marrow infusion. Results in patients who did or did not subsequently develop GVHD post-BMT were compared. Within 2 weeks of marrow infusion, patients who developed grades 2-4 GVHD had significantly higher percentages and absolute numbers of CD8+ T cells and a lower fraction of CD56+ natural killer (NK) cells than individuals who remained free of GVHD. Thirty-five percent of patients whose PBL were greater than 25{\%} CD8+ in the second posttransplant week developed GVHD, compared with only 3{\%} of patients who had ≤25{\%} CD8+ cells (odds ratio 37.8; 95{\%} confidence interval [Cl] 4.1 to 397). A subgroup of patients at very high risk for GVHD could be identified based on the combined frequency of CD8+ T cells and NK cells in blood. Seventy-five percent of patients with greater than 25{\%} CD8+ cells and ≤45{\%} CD56+ cells during week 2 post-BMT developed GVHD, compared with only 11{\%} of the remaining patients (odds ratio 24.9; 95{\%} Cl, 5.3 to 117.0). None of the 23 patients with both less than 25{\%} CD8+ cells and greater than 45{\%} CD56+ cells in the second posttransplant week developed grades 2-4 GVHD. Our findings indicate that CD8+ T cells play an important role in the pathogenesis of GVHD in humans. Analysis of immune reconstitution early after BMT is useful in predicting the onset of GVHD and can help direct the implementation of treatment strategies before the appearance of clinical manifestations. Such interventions may decrease the morbidity and mortality associated with allogeneic BMT and ultimately improve overall survival.",
author = "Soiffer, {Robert J.} and Ren{\'e} Gonin and Christine Murray and Michael Robertson and Keith Cochran and Steven Chartier and Christine Cameron and John Daley and Herbert Levine and Nadler, {Lee M.} and Jerome Ritz",
year = "1993",
month = "10",
day = "1",
language = "English (US)",
volume = "82",
pages = "2216--2223",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation

AU - Soiffer, Robert J.

AU - Gonin, René

AU - Murray, Christine

AU - Robertson, Michael

AU - Cochran, Keith

AU - Chartier, Steven

AU - Cameron, Christine

AU - Daley, John

AU - Levine, Herbert

AU - Nadler, Lee M.

AU - Ritz, Jerome

PY - 1993/10/1

Y1 - 1993/10/1

N2 - Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT). Because GVHD is frequently refractory to treatment, the early identification of high-risk patients could have significant clinical value. To identify such patients, we examined early immunologic recovery in 136 patients with hematologic malignancies who received anti-T12 (CD6)-purged allogeneic bone marrow over a 9-year period. The majority of patients received marrow from HLA-matched sibling donors after ablation with cyclophosphamide and total body irradiation. No patients received any immune suppressive medications for GVHD prophylaxis. The fraction and absolute numbers of peripheral blood lymphocytes (PBL) expressing the CD3, CD4, CD8, and CD56 surface antigens were determined weekly by immunofluorescence analysis in patients beginning 8 to 14 days (week 2) after marrow infusion. Results in patients who did or did not subsequently develop GVHD post-BMT were compared. Within 2 weeks of marrow infusion, patients who developed grades 2-4 GVHD had significantly higher percentages and absolute numbers of CD8+ T cells and a lower fraction of CD56+ natural killer (NK) cells than individuals who remained free of GVHD. Thirty-five percent of patients whose PBL were greater than 25% CD8+ in the second posttransplant week developed GVHD, compared with only 3% of patients who had ≤25% CD8+ cells (odds ratio 37.8; 95% confidence interval [Cl] 4.1 to 397). A subgroup of patients at very high risk for GVHD could be identified based on the combined frequency of CD8+ T cells and NK cells in blood. Seventy-five percent of patients with greater than 25% CD8+ cells and ≤45% CD56+ cells during week 2 post-BMT developed GVHD, compared with only 11% of the remaining patients (odds ratio 24.9; 95% Cl, 5.3 to 117.0). None of the 23 patients with both less than 25% CD8+ cells and greater than 45% CD56+ cells in the second posttransplant week developed grades 2-4 GVHD. Our findings indicate that CD8+ T cells play an important role in the pathogenesis of GVHD in humans. Analysis of immune reconstitution early after BMT is useful in predicting the onset of GVHD and can help direct the implementation of treatment strategies before the appearance of clinical manifestations. Such interventions may decrease the morbidity and mortality associated with allogeneic BMT and ultimately improve overall survival.

AB - Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT). Because GVHD is frequently refractory to treatment, the early identification of high-risk patients could have significant clinical value. To identify such patients, we examined early immunologic recovery in 136 patients with hematologic malignancies who received anti-T12 (CD6)-purged allogeneic bone marrow over a 9-year period. The majority of patients received marrow from HLA-matched sibling donors after ablation with cyclophosphamide and total body irradiation. No patients received any immune suppressive medications for GVHD prophylaxis. The fraction and absolute numbers of peripheral blood lymphocytes (PBL) expressing the CD3, CD4, CD8, and CD56 surface antigens were determined weekly by immunofluorescence analysis in patients beginning 8 to 14 days (week 2) after marrow infusion. Results in patients who did or did not subsequently develop GVHD post-BMT were compared. Within 2 weeks of marrow infusion, patients who developed grades 2-4 GVHD had significantly higher percentages and absolute numbers of CD8+ T cells and a lower fraction of CD56+ natural killer (NK) cells than individuals who remained free of GVHD. Thirty-five percent of patients whose PBL were greater than 25% CD8+ in the second posttransplant week developed GVHD, compared with only 3% of patients who had ≤25% CD8+ cells (odds ratio 37.8; 95% confidence interval [Cl] 4.1 to 397). A subgroup of patients at very high risk for GVHD could be identified based on the combined frequency of CD8+ T cells and NK cells in blood. Seventy-five percent of patients with greater than 25% CD8+ cells and ≤45% CD56+ cells during week 2 post-BMT developed GVHD, compared with only 11% of the remaining patients (odds ratio 24.9; 95% Cl, 5.3 to 117.0). None of the 23 patients with both less than 25% CD8+ cells and greater than 45% CD56+ cells in the second posttransplant week developed grades 2-4 GVHD. Our findings indicate that CD8+ T cells play an important role in the pathogenesis of GVHD in humans. Analysis of immune reconstitution early after BMT is useful in predicting the onset of GVHD and can help direct the implementation of treatment strategies before the appearance of clinical manifestations. Such interventions may decrease the morbidity and mortality associated with allogeneic BMT and ultimately improve overall survival.

UR - http://www.scopus.com/inward/record.url?scp=0027360966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027360966&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 2216

EP - 2223

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -